Company Overview - Proactive is a financial news and online broadcast organization that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates across key finance and investing hubs with offices in London, New York, Toronto, Vancouver, Sydney, and Perth [2] Content Production - Proactive's editorial team produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1] - The content covers a wide range of topics, including medium and small-cap markets, blue-chip companies, commodities, biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is committed to adopting technology to enhance workflows, utilizing automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [4][5]

Core Insights - Gossamer Bio's experimental drug for a serious lung and heart condition failed to meet the primary endpoint in a late-stage clinical trial [1] Company Summary - Gossamer Bio announced the failure of its experimental drug in a late-stage study, which is a significant setback for the company [1]

Core Viewpoint - Gilead Sciences has agreed to acquire the remaining shares of Arcellx, valuing the deal at $7.8 billion, leading to a significant increase in Arcellx's share price towards a new record [1] Company Summary - Gilead Sciences is expanding its portfolio by purchasing the remaining equity of Arcellx, a biotechnology company, indicating a strategic move to enhance its market position [1] - Arcellx's shares experienced a notable surge in early trading, reflecting positive investor sentiment following the acquisition announcement [1]

Core Viewpoint - South Korea has partially won its challenge against an arbitration ruling related to the 2015 merger of two Samsung affiliates, with the court overturning part of the award that required the government to pay approximately $100 million to Elliott [1][2]. Group 1: Arbitration Case Details - The arbitration award was issued by the Permanent Court of Arbitration in 2023, ordering South Korea to pay Elliott around $100 million [1]. - Elliott's lawsuit focused on the involvement of South Korea's National Pension Service in approving the $8 billion merger between Samsung C&T and Cheil Industries, where Elliott was a minority stakeholder [2]. - The High Court initially rejected South Korea's challenge regarding the tribunal's jurisdiction under a free trade agreement with the U.S., but the Court of Appeal later allowed South Korea's appeal [2]. Group 2: Court Rulings and Implications - Judge David Foxton overturned part of the arbitration award concerning the National Pension Service's vote in favor of the merger [2]. - The judge stated that Elliott's claims related to the actions of the administration of former President Park Geun-hye should be sent back to the arbitration tribunal for further consideration [2]. - The South Korean government described the ruling as a "valuable victory" [2].

This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.By [Callum Keown]ShareResize---ReprintsIn this ...

每经AI快讯，2月23日，吉利德科学公司盘前股价下跌1.3%。 ...

Company Overview - Arcellx is a clinical-stage biotechnology company focused on proprietary cell therapy platforms to address unmet medical needs in oncology [5] - The company has a specialized pipeline targeting multiple myeloma and hematologic malignancies, positioning itself at the forefront of next-generation immunotherapies [5] - As of February 17, 2026, Arcellx's market capitalization is $4.06 billion, with a revenue of $35.90 million and a net income of -$217.90 million [4] Recent Developments - Perceptive Advisors disclosed a sale of 1,002,282 shares of Arcellx, valued at approximately $79.96 million, during the fourth quarter of 2026 [2][1] - The quarter-end value of Arcellx's position declined by $107.06 million, reflecting both the share reduction and share price movements [2] - Arcellx shares were priced at $70.20, representing a 9.2% increase over the past year, but underperforming the S&P 500 by 4.3 percentage points [7] Pipeline and Product Focus - Arcellx develops immunotherapies, primarily focusing on CART-ddBCMA for relapsed or refractory multiple myeloma, with additional candidates targeting acute myeloid leukemia, myelodysplastic syndrome, and solid tumors [8] - The company's anito-cel is in Phase 3 trials for relapsed or refractory multiple myeloma in partnership with Gilead's Kite unit, indicating a more advanced position compared to early proof-of-concept data [10] Market Position and Competition - The recent share sale by Perceptive Advisors indicates a strategic move as Arcellx faces competition not only from other approved CAR-T therapies but also from new delivery models [6] - The volatility in Arcellx's stock price highlights the rapid shifts in sentiment within the biotechnology sector, particularly following data releases and market reactions [9][10] - Analysts from Guggenheim and Citi suggested that the sell-off following a three-patient data set was overdone, indicating potential for recovery [9]

Core Insights - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company adopts a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible to both seasoned and novice investors [1] Company Mission - The mission of Allka Research is to empower individuals financially by sharing knowledge and insights through platforms like Seeking Alpha [1] - The company aims to provide thought-provoking analyses and informed perspectives to foster a community of informed investors [1] - Allka Research seeks to demystify investing, inspiring confidence in readers to navigate the markets intelligently [1]

Core Insights - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company adopts a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible for both seasoned and novice investors [1] Company Mission - The mission of Allka Research is to empower individuals financially by sharing knowledge and insights through the Seeking Alpha platform [1] - The company aims to provide thought-provoking analyses and informed perspectives to foster a community of informed investors [1] - Allka Research seeks to demystify investing, inspiring confidence in readers to navigate the markets intelligently [1]

Core Insights - Gilead Sciences, Inc. (GILD) reported strong fourth-quarter and full-year 2025 results, with HIV product sales increasing by 6%, driven by a 7% growth in Biktarvy and a 47% surge in its prevention portfolio [1][2][10] Group 1: HIV Product Performance - Biktarvy holds over 52% market share in the HIV treatment market and is the most prescribed therapy for both treatment-naïve and switch patients [2] - Descovy's sales increased by 31% year over year to $2.8 billion, accounting for more than 45% of the U.S. market share in pre-exposure prophylaxis (PrEP) [3] - The FDA approved injectable lenacapavir (Yeztugo), which offers a twice-yearly dosing schedule, enhancing adherence compared to daily oral regimens [4] Group 2: Financial Projections and Growth Drivers - Despite a $900 million headwind from the Medicare Part D redesign, HIV sales grew 10% when excluding this impact, surpassing management's annual target of 5% growth [2][10] - Gilead expects total HIV sales to grow approximately 6% year over year in 2026, with potential growth of 8% when excluding pricing pressures and channel mix shifts [6] - Early uptake of Yeztugo generated $150 million in 2025, with projected revenues of approximately $800 million in 2026 [5] Group 3: Research and Development Initiatives - Positive phase III results from ARTISTRY-1 and ARTISTRY-2 studies for the investigational BIC/LEN regimen increase the likelihood of regulatory approval, potentially launching by year-end [7] - Gilead is collaborating with Merck to advance its HIV pipeline, with data from studies on islatrovir plus lenacapavir expected in 2026 [8] - Plans to initiate a phase III study evaluating lenacapavir plus broadly neutralizing antibodies are set for the second half of the year [9] Group 4: Competitive Landscape - Gilead faces competition from major players like GSK and Merck in the HIV treatment market, with GSK's growth driven by long-acting injectable medicines [11] - Merck markets doravirine and is evaluating a once-daily oral regimen for treatment-naïve adults with HIV-1 infection [12] Group 5: Stock Performance and Valuation - GILD shares surged 45.9% over the past year, outperforming the industry's growth of 19.6% [15] - The current price/earnings ratio for GILD is 17.46x forward earnings, higher than its historical mean but lower than the large-cap pharma industry average of 18.51x [16]